BMP10 Peptide Biomarker for Atrial Fibrillation Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable biomarkers for assessing atrial fibrillation, diagnosing its severity, and predicting stroke risk associated with the condition.
Innovation Solution
Determining the amount of BMP10-type peptide in a subject's sample, optionally combined with other biomarkers like natriuretic peptides, ESM-1, Ang2, and FABP3, and comparing these levels to reference amounts to assess atrial fibrillation, diagnose heart failure, and predict hospitalization risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used for atrial fibrillation, then simplicity and clinical relevance are maintained, but reliability of assessment and diagnosis is insufficient
Solution Approach 1:
The patent applies parameter changes by introducing new measurable parameters (BMP10-type peptide levels, N-terminal prosegment levels) to improve the reliability of atrial fibrillation assessment. The diagnostic method measures specific biochemical parameters in blood samples that correlate with atrial fibrillation severity and stroke risk, thereby enhancing diagnostic reliability without requiring complex procedural changes
Solution Approach 2:
The patent implements universality by creating a multi-functional diagnostic approach using BMP10-type peptides that can simultaneously assess atrial fibrillation presence, differentiate between paroxysmal and persistent forms, and predict stroke risk. This single biomarker system serves multiple diagnostic functions, improving reliability while maintaining practical simplicity
2Measurement precision
If current biomarker methods are used, then ease of operation is maintained, but measurement precision for stroke risk prediction is insufficient
Solution Approach 1:
The patent improves measurement precision by introducing specific biochemical parameters (BMP10-type peptide concentrations, N-terminal prosegment levels) that provide more accurate stroke risk stratification. The method establishes reference ranges and cutoff values for these parameters, enabling precise risk prediction while maintaining ease of operation through standard blood sampling and immunoassay techniques
3Reliability
If traditional classification methods are used, then simplicity is maintained, but ability to differentiate AF severity and predict outcomes is insufficient
Solution Approach 1:
The patent enhances classification reliability by introducing quantitative biochemical parameters (BMP10 levels, N-terminal prosegment ratios) that objectively differentiate between paroxysmal and persistent atrial fibrillation. These parameter-based classifications provide more reliable stratification than traditional clinical criteria alone, enabling better prediction of stroke risk and treatment response
Data Source
AI summary
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.